MALVERN, Pa., Dec. 9, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that the U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT® (vasopressin injection, USP) at the company's newest aseptic manufacturing facility in Indore, India. The 20,000-square-foot site increases Endo's sterile injectable production capacity and expands the future growth potential for its Injectable Solutions business.
"This is a significant milestone for Endo as we invest and innovate in our sterile injectables business," said Scott Hirsch, Interim CEO of Endo. "The FDA approval of our newest manufacturing site demonstrates our commitment to meeting product demand and delivering quality medicines to patients."
The Indore facility is designed specifically for aseptic manufacturing of sterile injectable products—a difficult and highly specialized production capability. The site is expected to eventually produce medicines in syringes, in addition to vials. Read More >
Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital systems and with retail generic medications, we have developed an unmatched understanding of those we serve. We will never stop learning how to make a real difference in people's lives. We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, innovating together to add value where it matters—from manufacturing to treatment—so that healthcare providers can focus on patient care. We deliver high-quality, affordable generic medicines to patients in need through excellence in development, manufacturing, and commercialization. Drawing from over four decades of experience in the U.S. generic pharmaceutical market, we have built a well-established reputation for compliance and exceptional customer service.
